We enter the final stretch of the year and pharmaceutical companies take on even more prominence. The market knows that they must not be lost sight of due to their role in the entire coronavirus pandemic, and they know that the time has come to speak, in one sense or another, of go 'putting the cards on the table' and, ultimately, to position itself at a time when many are waiting for news about the treatment against Covid-19.
This week there has been news for all tastes, good and bad, but what is clear is that the sector is moving and that there will be much more movement by the end of the year. To begin with, on Thursday, October 22, the expert committee of the US FDA (Food and Drug Administration) meets to assess the advances in treatments against the virus, and it is to be expected that, with this appointment in the background, there are more announcements and news about pharmaceutical companies and their progress.
FROM JOHNSON TO JOHNSON TO REMDESIVE …
This week there have been clear and sector-related obscure. It is striking that, while some foreign companies suffered, other Spanish companies triumphed on the stock market for the good news about their business.
On Tuesday Johnson & Johnson announced that suspends trials of its vaccine against Covid-19 and on Wednesday it became known that Eli Lilly has done his own with the trials of his therapy against the virus. They were two bad news that ended up being crowned with what was learned on Friday about the drug Remdesivir, from Gilead Sciances. According to the WHO (World Health Organization), it is not effective when it comes to curbing the mortality of the coronavirus.
There have been several 'blows' that have opened the eyes of the market, which has abandoned that certainty that the vaccine will be ready before the end of the year. Now there is open talk of mid-2021, which is a 'jug of cold water'.
… AND FROM GRIFOLS TO PHARMAMAR
Faced with these unfavorable news, the Ibex pharmaceutical companies have been protagonists for soaring in the stock market thanks to the positive news.
Grifols was flying on Thursday (+ 8%) after it was learned that Vertex Pharma has abandoned a project that could potentially compete with its plasma-based products. There are good feelings in recent times around the Catalan, especially after the Donald Trump Administration in August grant emergency authorization to the use of plasma to treat patients hospitalized by Covid, the field in which the company is working. Last week, Grifols reported the launch with coronavirus patients of the anti-SARS-CoV-2 hyperimmune immunoglobulin trial, in which it participates together with Emergent BioSolutions, CSL Behring and Takeda Pharmaceutical.
PharmaMar has been the other 'graceful' Spanish pharmaceutical company with strong increases in the stock market thanks to the good news. On Friday soared after communicating progress in its trial with the drug Aplidin to face the coronavirus. PharmaMar announced that it will begin, in the coming days, conversations with the regulatory agencies to define the next phase III study of plitidepsin registration in patients with Covid-19 who require hospitalization.
Next week, specifically Monday, PharmaMar holds a press conference to explain how your investigation against Covid is going, while on Tuesday, Rovi also meets with the media to deepen its agreement with the American company Moderna to manufacture the filling and finishing of its vaccine against the virus.
There is movement in the sector. And there will be much more.
. (tagsToTranslate) PharmaMar (t) Grifols (t) J&J (t) Lilly … (t) revolution (t) pharmaceuticals (t) straight line (t) end (t) year (t) Category: All (t) Category : Company News (t) Category: Pulsos (t) Category: Sectorial: Health Technology (t) mostread_ultimas (t) mostread_fundsnews (t) mostread_empresas